REVIEW article
Front. Endocrinol.
Sec. Clinical Diabetes
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1557813
Surrogate Endpoints in Diabetic Kidney Disease: Current Perspectives and Future Directions
Provisionally accepted
- Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Diabetic kidney disease (DKD) represents a leading complication of diabetes, frequently progressing to end-stage renal disease (ESRD), which significantly impairs patients' quality of life and imposes substantial healthcare burdens. Consequently, early detection and intervention in DKD are paramount. The incorporation of surrogate endpoints in clinical trials has emerged as a pivotal strategy for assessing the efficacy of novel therapies, facilitating the reduction of trial duration and associated costs. Currently, the rate of change in estimated glomerular filtration rate (eGFR) and urinary albumin excretion, either independently or in combination, serve as reliable surrogate endpoints for evaluating DKD progression. Although novel biomarkers such as KIM-1 and TNFR2 are not yet recommended as standalone surrogate endpoints for DKD, they hold potential when used in combination with established markers, such as eGFR slope and urinary albumin change rate, to improve the prediction of ESRD risk. While omics-based indicators demonstrate promise in DKD research, their utility requires further validation, particularly through long-term follow-up and dynamic monitoring, to establish their effectiveness and clinical applicability. Future research should prioritize the validation and optimization of potential surrogate endpoints through long-term follow-up studies and large-scale cohorts.
Keywords: Diabetic kidney disease, Surrogate endpoints, ESRD, eGFR slop, UACR, Novel biomarkers
Received: 06 Feb 2025; Accepted: 30 Apr 2025.
Copyright: © 2025 Cao, Zhang, Ma, Miao and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Can Cao, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.